{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:27:02Z","timestamp":1791084422408,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcyt.2024.11.016","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T07:33:19Z","timestamp":1733124799000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espa\u00f1ol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Gonz\u00e1lez Vicent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Panesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vinagre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Mozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Olivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"D\u00edaz de Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.11.016_bib0001","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCR-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0002","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.14965","article-title":"Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003\/2007 trial","volume":"180","author":"Kuhlen","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0004","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2018.09.016","article-title":"Outcomes after second hematopoietic cell transplant for children and young adults with relapsed acute leukemia","volume":"25","author":"Lund","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0006","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S274551","article-title":"Post-hematopoietic cell transplantation relapsed acute lymphoblastic leukemia: current challenges and future directions post-hematopoietic cell transplantation relapsed acute lymphoblastic leukemia: current challenges and future directions","volume":"16","author":"Varadarajan","year":"2023","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0009","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2021.777108","article-title":"Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant?","volume":"9","author":"Merli","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0011","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0012","first-page":"1","article-title":"Total body irradiation forever? optimising chemotherapeutic options for irradiation-free conditioning for paediatric acute lymphoblastic leukaemia","volume":"9","author":"Hassine","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","article-title":"Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia","volume":"27","author":"Yalniz","year":"2021","journal-title":"Transplantat Cellular Ther"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0014","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0015","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0016","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jcyt.2024.11.016_bib0017","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V106.11.2012.2012","article-title":"Treatment of minimal residual disease (MRD) with donor lymphocyte infusions (DLI) in acute leukemia patients undergoing an allogeneic hemopoietic stem cell transplants (HSCT)","volume":"106","author":"Dominietto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0018","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.16647","article-title":"Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)","volume":"190","author":"Fuster","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/ejh.14132","article-title":"Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia","volume":"112","author":"Gupta","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2018.1.16","article-title":"Are CAR T cells better than antibody or HCT therapy in B-ALL?","volume":"2018","author":"Pulsipher","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0023","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0024","article-title":"Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2017.03.001","article-title":"Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors","volume":"57","author":"Gonz\u00e1lez-Vicent","year":"2017","journal-title":"Leukemia Res"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0026","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0027","doi-asserted-by":"crossref","first-page":"e07005","DOI":"10.1136\/bmjopen-2022-070051","volume":"13","author":"Sakaguchi","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcyt.2024.11.016_bib0028","first-page":"3557","article-title":"Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation","volume":"109","author":"Penack","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jcyt.2024.11.016_bib0029","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-022-00352-w","article-title":"Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia\/lymphoma","volume":"7","author":"Dai","year":"2022","journal-title":"Biomark Res"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:24:19Z","timestamp":1744446259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1465324924009423"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.016","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espa\u00f1ol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}